Literature DB >> 10532609

Effects of granulocyte-colony-stimulating factor on potential normal granulocyte donors.

J McCullough1, M Clay, G Herr, J Smith, D Stroncek.   

Abstract

BACKGROUND: The use of granulocyte-colony-stimulating factor (G-CSF) to increase the granulocyte count and the yield from leukapheresis in normal donors is leading to renewed interest in granulocyte transfusion. Therefore, it is important to understand the side effects of G-CSF. STUDY DESIGN AND METHODS: We studied the effect of G-CSF on peripheral blood counts and recorded the side effects experienced 24 hours after an injection of G-CSF in normal subjects donating peripheral blood progenitor cells for research.
RESULTS: Following administration of G-CSF to 261 donors, the neutrophil count increased to 20.6 to 24.5 x 10(9) per microL depending on the dose of G-CSF. This represented a 6.2 to 7.4-fold increase over the neutrophil count before G-CSF administration. Of all donors, 69 percent experienced one or more side effects. The most common effects were: muscle and bone pain, headache, fatigue, and nausea. There was a relationship between the dose of G-CSF and the likelihood of experiencing a side effect. Most side effects were mild, but about 75 percent of donors took analgesics because of them.
CONCLUSIONS: In a granulocyte donation program involving G-CSF stimulation, about two-thirds of donors would experience one or more side effects, but these would usually be mild and well tolerated.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10532609     DOI: 10.1046/j.1537-2995.1999.39101136.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  5 in total

1.  Efficacy and side effects of granulocyte collection in healthy donors.

Authors:  Franziska Brockmann; Michael Kramer; Martin Bornhäuser; Gerhard Ehninger; Kristina Hölig
Journal:  Transfus Med Hemother       Date:  2013-07-19       Impact factor: 3.747

2.  Recombinant granulocyte colony-stimulating factor-transferrin fusion protein as an oral myelopoietic agent.

Authors:  Yun Bai; David K Ann; Wei-Chiang Shen
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-03       Impact factor: 11.205

3.  Efficacy of plerixafor in children with malignant tumors failing to mobilize a sufficient number of hematopoietic progenitors with G-CSF.

Authors:  A A Maschan; D N Balashov; E E Kurnikova; P E Trakhtman; E V Boyakova; E V Skorobogatova; G A Novichkova; M A Maschan
Journal:  Bone Marrow Transplant       Date:  2015-04-27       Impact factor: 5.483

4.  Peripheral mononuclear blood cell apheresis in a preclinical ovine model.

Authors:  Helen Lydon; Roger Brooks; Andrew McCaskie; Frances Henson
Journal:  BMC Vet Res       Date:  2018-02-13       Impact factor: 2.741

Review 5.  Granulocyte transfusions in children and adults with hematological malignancies: benefits and controversies.

Authors:  Chiara Cugno; Sara Deola; Perla Filippini; David F Stroncek; Sergio Rutella
Journal:  J Transl Med       Date:  2015-11-16       Impact factor: 5.531

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.